AbbVie Secures Positive CHMP Opinion for Atogepant for the Preventive Treatment of Adults with Migraine
- Friday, June 23, 2023, 7:13
- PR Newswire
- Add a comment
If approved by the European Commission (EC), atogepant will be the first and only once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) for the prophylaxis of migraine in adults who have four or more migraine days per month The…
About the Author
admin has written 21640 stories on this site.